The success rate of clarithromycin and furazolidone treatment regimen with or without using pyloshot in patients with refractory Helicobacter pylori infection

Evaluation of success rate of two treatment clarithromycin baced and furazolidone baced with and without pyloshot in patients with refractory Helicobacter pylori infection

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230827059273N1

Enrollment

272

Registered

2023-10-15

Start date

2024-03-20

Completion date

Unknown

Last updated

2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter Pylori.

Interventions

Intervention 1: Intervention group: Include patients with with refractory Helicobacter pylori infection who, despite the treatment, still have positive fecal antigen, and the treatment regimens based

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with treatment-resistant Helicobacter pylori infection who still have positive fecal antigen despite treatment.

Exclusion criteria

Exclusion criteria: Pregnant and lactating women

Design outcomes

Primary

Measure	Time frame
Helicobacter pylori fecal antigen negativity after two months of treatment. Timepoint: H. pylori fecal antigen measurement once two months after the end of treatment. Method of measurement: Stool test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Somaie Matin

Ardabil University of Medical Sciences

nakhostin.babak@gmail.com+98 914 354 7053

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026